Treatment Guide•7 min read•September 17, 2026

Patient Screening for Laser & RF Treatments: Contraindications, Medications & Consent

A practice evaluating energy-based devices tends to focus its attention on the platform: wavelengths, pulse durations, cooling, spot sizes, treatment speed. Those specifications matter. But the variable that most often separates a routine treatment from a complication is not the device setting — it is whether the person in the chair should have been treated with that device, on that day, at all.

Patient screening is the least glamorous part of an aesthetic practice and the part that carries the most risk when it is compressed. It is also the step most likely to erode over time: a protocol written carefully at launch becomes a form the patient fills out in the waiting room, then a form nobody reads. What follows is a framework for building a screening process that survives a busy schedule, organized around the questions that actually change a treatment decision. It is not a clinical protocol, and it does not replace the instructions for use that ship with your platform or the judgment of the supervising provider.

The consultation is a screening step, not a sales step

When the consultation is structured primarily to convert, screening becomes something that happens around the edges of a conversation about packages and pricing. The practices with the fewest adverse events tend to treat these as two separate conversations, with the clinical one first and the commercial one downstream of a decision that the patient is an appropriate candidate.

Establish who performs the evaluation and whether your state permits that person to do it — assessment authority and treatment authority are frequently governed by different rules.
Document the patient's goal in their own words, then record whether the technology you have can reasonably address it. The honest answer is sometimes no.
Review prior aesthetic treatments, including where and when, and any reaction to them.
Ask about the patient's history of scarring, including keloid or hypertrophic scarring, and about any history of post-inflammatory pigment change.
Confirm pregnancy and breastfeeding status where relevant, and follow the platform's instructions for use on that point rather than a general rule of thumb.
Note anything that suggests unrealistic expectations, and resolve it before booking rather than after the first session.

Separate the absolute from the relative

Screening lists are more useful when they distinguish between conditions that rule a treatment out and conditions that change how it is delivered. Collapsing the two produces either over-caution, where appropriate candidates are turned away, or under-caution, where a relative contraindication is waved through because it was not on the short list. Each platform's instructions for use define its own contraindications, and those govern.

Active infection, open lesions, or inflammatory skin conditions in the treatment area generally defer a session until the area has resolved.
A suspicious pigmented lesion in the treatment field is a referral, not a treatment target — a lesion that warrants evaluation should be evaluated before any energy is delivered near it.
A history of herpes simplex in the treatment area is commonly a prophylaxis-and-planning question rather than an exclusion.
Autoimmune and photosensitive conditions vary widely in relevance, and belong in a conversation with the patient's treating physician rather than a yes/no box on a form.
Recent aesthetic procedures in the same area — chemical peels, injectables, other energy treatments — usually govern timing rather than eligibility.
Poorly controlled systemic conditions affecting wound healing warrant medical clearance before a course of treatment is planned.

Medications and supplements change the picture more than patients expect

Patients routinely omit medications on intake forms, not to conceal them but because they do not connect a prescription to a skin treatment. Asking an open question in the room, after the form has been completed, surfaces more than the form does — and a short, specific prompt works better than a general one.

Systemic retinoids have a well-established waiting period in most device instructions for use; confirm the interval your platform specifies rather than applying a remembered number.
Photosensitizing medications — certain antibiotics, diuretics, and others — can change the skin's response, and patients seldom volunteer them.
Anticoagulants and antiplatelet agents affect bruising and are worth knowing before, not after.
Topical actives in the patient's home routine, including retinoids and exfoliating acids, usually need a pause window on either side of treatment.
Supplements with photosensitizing or blood-thinning effects belong in the same question, since patients rarely classify them as medication.
Recent injectable treatments and their timing relative to an energy-based session should be confirmed with the provider who performed them.

Skin type, recent sun, and the tanning question

Fitzpatrick typing remains the working shorthand for how skin is likely to respond to light-based energy, and it is most useful when it is assessed in person rather than self-reported. A patient's stated type and their observed type differ often enough that the assessment is worth doing in the room, alongside a direct question about recent and planned sun exposure.

Assess and record Fitzpatrick type at the consultation, and re-check it seasonally for patients on a treatment course.
Ask about sun exposure and self-tanning products in the weeks before treatment, and about travel plans in the weeks after.
For light-based platforms, the wavelength and pulse duration in play change how much recent tanning matters — a 1064 nm Nd:YAG behaves differently from a shorter wavelength.
Multi-wavelength systems such as SANDRO DUAL, which pairs 755 nm and 1064 nm, and V-LASER, which combines 532 nm KTP with 1064 nm Nd:YAG, give a practice more room to match the wavelength to the patient rather than the other way around.
Q-switched and picosecond platforms such as PASTELLE PRO, PICO MAJESTY, and PICO ALEX carry their own screening considerations for pigment work, particularly where post-inflammatory change is a concern.
A test spot, where the platform's instructions for use provide for one, is a screening tool and not an inconvenience.

Radiofrequency raises a different set of questions

Because radiofrequency delivers energy by a different mechanism than light, the screening conversation for an RF platform is not the same conversation, and a practice that runs both should not reuse one form for the other. Monopolar RF platforms such as OLIGIO X, the next-generation monopolar RF platform, have their own instructions for use, and those are the governing document.

Implanted electronic devices — pacemakers, defibrillators, neurostimulators, and similar — are a specific and standard question for any RF platform.
Metal implants, plates, and permanent fillers in or near the treatment area should be identified and located before treatment, not discovered during it.
Grounding and return-pad placement follow the manufacturer's instructions precisely; this is not an area for local improvisation.
Recent injectable or thread treatments in the treatment area affect timing and belong in the intake questions.
Sensory impairment in the treatment area matters, because patient feedback on heat is part of how the treatment is delivered safely.
Where a patient has an implanted device of any kind, medical clearance from the managing physician is the conservative and defensible path.

Consent that documents a conversation, not a signature

A consent form that a patient signs without discussion documents very little. The version that holds up is the one that records what was actually explained — including the parts a practice would rather not dwell on, such as the possibility that a course of treatment does not produce the result the patient hoped for.

Use a device-specific and treatment-specific consent rather than one general form for every service on the menu.
State plainly that individual results vary and that a series may be required, and record that this was discussed.
List the expected post-treatment course and the specific signs that should prompt a call to the practice.
Record the screening answers themselves, not just the conclusion — the intake responses are the evidence that screening happened.
Photograph the treatment area under consistent lighting and positioning at baseline, and keep the standard.
Re-screen at each visit in a treatment series; medications, sun exposure, and health status all change between sessions.

Make the process survivable on a full schedule

A screening protocol only works if it can be completed on a day when the schedule is full and the practice is short-staffed. That usually means it has to be shorter and more structured than the version written at launch — a defined set of questions, asked the same way every time, with a clear rule for what triggers a pause and who makes that call.

Keep one screening checklist per platform, stored with the device file and the instructions for use.
Define in advance who has the authority to defer a treatment, and make clear that deferring is never a decision anyone will be second-guessed for.
Build the re-screen into the visit workflow rather than leaving it to memory.
Include screening in the training every new operator receives, alongside parameters and safety.
Review the checklist against the current instructions for use whenever a platform receives a software or protocol update.

This is one of the areas where the manufacturer relationship matters in practice. WONTECH designs and manufactures its own laser and RF systems in-house and supports the US market from operations in Livermore, California, which means questions about a platform's instructions for use, screening considerations, and training protocols are answered by the team that engineered the device rather than routed through a distributor. A demo with your clinical team is the practical setting to walk through how screening and treatment planning would actually work on your schedule.

This article is educational and intended for licensed medical professionals evaluating device technology; it is not medical or legal advice, and it does not replace the manufacturer instructions for use, your state board rules, or the judgment of the supervising provider. Contraindications and screening requirements are device-specific and change over time, and individual results and circumstances vary. If you are evaluating a laser or RF platform and want to review screening and training with your team, a demo is the best next step.